Triple negative breast cancer is a subtype of breast cancer that does not have estrogen receptors, progesterone receptors, or high levels of HER2. Treatment decisions often depend on the cancer stage, tumor characteristics, genetic factors, and overall health of the individual. Modern treatment approaches may include chemotherapy, immunotherapy, surgery, radiation therapy, targeted treatments, and newer therapies for advanced disease. Ongoing research continues to improve understanding of this complex condition and identify additional treatment approaches. Learning about available options can help patients and families understand how treatment plans may be developed by qualified healthcare professionals.
Triple negative breast cancer is often treated using a combination of therapies because it does not respond to hormone therapy or HER2 targeted treatments used for other breast cancer subtypes. The treatment approach can vary depending on whether the cancer is early stage, locally advanced, recurrent, or metastatic. Healthcare professionals may consider tumor size, lymph node involvement, genetic testing results, previous treatments, and the patient's overall health when developing an individual treatment plan.
Chemotherapy remains an important treatment option for many people with triple negative breast cancer. It may be given before surgery, known as neoadjuvant chemotherapy, to reduce the size of the tumor. It can also be given after surgery to help address cancer cells that may remain in the body.
Surgery may involve removing the tumor through breast conserving surgery or removing the breast through mastectomy. The appropriate surgical approach depends on factors such as tumor size, location, cancer stage, and individual medical considerations. Radiation therapy may also be recommended after surgery in certain situations to reduce the likelihood of cancer returning in the treated area.
Common treatment approaches may include:
Treatment may involve several specialists, including medical oncologists, surgical oncologists, radiation oncologists, pathologists, and other healthcare professionals. Regular monitoring can also help healthcare teams assess treatment response and manage possible side effects.
Modern research has expanded treatment options for some people with triple negative breast cancer. Immunotherapy is one approach that may be used in selected cases. These treatments are designed to help the immune system recognize and respond to cancer cells. Eligibility can depend on the cancer stage, biomarker testing, and other clinical factors.
Targeted therapies may also be considered for people with specific genetic changes. For example, certain treatments may be used for individuals with inherited BRCA mutations or other relevant molecular characteristics. Advanced or metastatic triple negative breast cancer may also be evaluated for antibody drug conjugates and other specialized treatment approaches.
Modern and emerging options may include:
Research into triple negative breast cancer continues to explore ways to improve treatment response and better understand why different tumors behave differently. Clinical trials may provide access to investigational approaches while also contributing to scientific knowledge. Treatment choices should be discussed with qualified healthcare professionals, who can explain potential benefits, limitations, risks, and side effects based on an individual's specific medical situation.